Please assess the completion status of the following clinical trial:

Trial Title: A Study of Psilocybin for Major Depressive Disorder (MDD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 21 to 65 years old~* Able to swallow capsules~* If of childbearing potential, agree to practice an effective means of birth control throughout the duration of the study~* Have an identified support person and agree to be accompanied home by that person following dosing~* Have sustained moderate-severe depression symptoms at Screening and Baseline~* Meet DSM-5 criteria for a diagnosis of major depressive disorder and are currently experiencing a major depressive episode of at least a 60-day duration at the time of screening~Exclusion Criteria:~* Women who are pregnant or who intend to become pregnant during the study or who are currently nursing~* Have any of the following cardiovascular conditions: uncontrolled hypertension, coronary artery disease, congenital long QT syndrome, cardiac hypertrophy, cardiac ischemia, congestive heart failure, myocardial infarction, tachycardia, artificial heart valve, a clinically significant screening ECG abnormality, or any other significant cardiovascular condition~* Have a history of stroke or Transient Ischemic Attack (TIA)~* Have moderate to severe hepatic impairment~* Have epilepsy~* Have insulin-dependent diabetes~* Have a positive urine drug test~* Nicotine dependence that would disallow an individual to be nicotine free for the 7-10 hours during the dosing period~* Meet DSM-5 criteria for schizophrenia spectrum or other psychotic disorders, including major depressive disorder with psychotic features, or Bipolar I or Bipolar II Disorder~* Meet DSM-5 criteria for antisocial personality disorder~* Meet DSM-5 criteria for a moderate or severe alcohol or drug use disorder

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Psilocybin (Type: EXPERIMENTAL): Participants will receive a single 25 mg dose of psilocybin along with the Set and Setting (SaS) protocol. Psilocybin is administered orally as a capsule and taken with water.
- Niacin (Type: ACTIVE_COMPARATOR): Participants will receive a single 100 mg dose of niacin along with the Set and Setting (SaS) protocol. Niacin is administered orally as a capsule and taken with water.

Based on this trial design, predict the completion outcome and termination type (if applicable).